Gil Y. Melmed

Gil Y. Melmed

Auto-generated profile, based on publicly available information

Gil Y. Melmed

Inflammatory Bowel and Immunobiology Research Institute, Karsh Division of Digestive and Liver Diseases, Cedars-Sinai, Los Angeles, California, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2021 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
GBGregory J. Botwin
Gregory J. Botwin
DLDalin Li
Dalin Li
JFJane Figueiredo
Jane Figueiredo
SCSusan Cheng
Susan Cheng
JBJonathan Braun
Jonathan Braun
GMGil Y. Melmed
Gil Y. Melmed
INTRODUCTION: Patients with immune-mediated inflammatory diseases such as inflammatory bowel disease (IBD) on immunosuppressive and biologic therapies were largely excluded from severe acute respiratory syndrome coronavirus-2 messenger RNA vaccine trials. METHODS: We evaluated adverse events (AE) after messenger RNA vaccination in 246 adults with IBD participating in a longitudinal vaccine registry. RESULTS: In general, AE frequency was similar to that reported in the general population. AEs were more common among younger patients and those with previous COVID-19. AEs were less common in individuals receiving advanced therapies with biologics or small-molecule inhibitors. DISCUSSION: Those with IBD and other immune-mediated inflammatory diseases can be reassured that the AE risk is likely not increased, and may be reduced, while on advanced therapies.

18 January 2018 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
VRVineet S Rolston
Vineet S Rolston
LBLaleh Boroujerdi
Laleh Boroujerdi
MLMillie D Long
Millie D Long
DMDermot P B McGovern
Dermot P B McGovern
WCWenli Chen
Wenli Chen
GMGil Y Melmed
Gil Y Melmed
Many women with inflammatory bowel disease (IBD) report changes in symptoms in association with hormonal changes during menses, pregnancy, and hormonal contraceptive use, suggesting a hormonal influence on disease activity. We aimed to identify and characterize IBD symptom fluctuations in women during times of hormonal variation. From June 2012 through September 2012, women enrolled in Crohn’s and Colitis Foundation of America Partners , an online Internet cohort of patients with IBD, were invited to participate in this study. Using a 5-point Likert scale, participants were asked to rate symptom changes during their menstrual cycle, pregnancy, the postpartum period, and after menopause. Clinical and demographic differences were assessed using univariate and multivariable methods. A total of 1,203 female patients with Crohn’s disease (CD) and ulcerative colitis (UC) participated (64% CD, 34% UC). Over half of the women with IBD reported worsening symptoms during menses. Symptom changes were similar between women with CD vs UC, except in pregnancy, where symptom worsening during pregnancy was more commonly seen in UC than CD (P = 0.02). Overall, women reporting symptom worsening were younger at the time of IBD diagnosis (P < 0.01), had lower quality of life (SIBDQ) scores (P < 0.01), and had a higher BMI (25 vs 24) than women without symptom worsening. Women with IBD report changes in symptom severity during times of hormone fluctuation. Further clarification of the role of hormones in IBD is warranted in order to understand these relationships and to identify potential management strategies for women with IBD and hormonally sensitive gastrointestinal symptoms.

1 December 2021 in Annals of Internal Medicine
Verified
Journal Article
Open access
GMGil Y. Melmed
Gil Y. Melmed
GBGregory J. Botwin
Gregory J. Botwin
KSKimia Sobhani
Kimia Sobhani
DLDalin Li
Dalin Li
JPJohn Prostko
John Prostko
DMDermot P.B. McGovern
Dermot P.B. McGovern

1 March 2023 in Crohn's & Colitis 360
Verified
Journal Article
Open access
PDF file
RPRemo Panaccione
Remo Panaccione
ECEric B Collins
Eric B Collins
GMGil Y Melmed
Gil Y Melmed
SVSeverine Vermeire
Severine Vermeire
SDSilvio Danese
Silvio Danese
SWSi-Tien Wang
Si-Tien Wang
Background: Given rapid innovation in advanced therapies for moderately to severely active ulcerative colitis (UC), we investigated their comparative efficacy and safety during induction and maintenance through network meta-analysis.Methods: Using Bayesian methods, endpoints of clinical remission and clinical response per Full Mayo score, and endoscopic improvement were assessed in bio-naive and -exposed populations. Safety was assessed in overall populations by all adverse events (AEs), serious AEs, discontinuation due to AEs, and serious infections. Phase 3 randomized controlled trials were identified via systematic literature review, including the following advanced therapies: infliximab, adalimumab, vedolizumab, golimumab, tofacitinib, ustekinumab, filgotinib, ozanimod, and upadacitinib. Random effects models were used to address between-study heterogeneity. Intent-to-treat (ITT) efficacy rates were calculated by adjusting maintenance outcomes by likelihood of induction response.Results: Out of 48 trials identified, 23 were included. Across all outcomes and regardless of prior biologic exposure, ITT efficacy rates were highest for upadacitinib, owing to its highest ranking for all efficacy outcomes in induction and for all but clinical remission during maintenance among bio-naive induction responders. For all advanced therapies versus placebo, there were no significant differences in serious AEs or serious infections across therapies. For all AEs, golimumab had higher odds versus placebo during maintenance; for discontinuation due to AEs, upadacitinib had lower odds versus placebo during induction, while ustekinumab and vedolizumab had lower odds versus placebo during maintenance.Conclusions: Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety across advanced therapies.

10 November 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
JFJane C Figueiredo
Jane C Figueiredo
NMNoah M. Merin
Noah M. Merin
OHOmid Hamid
Omid Hamid
SCSo Yung Choi
So Yung Choi
TLTucker Lemos
Tucker Lemos
AMAkil Merchant
Akil Merchant
Longitudinal studies of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine-induced immune responses in patients with cancer are needed to optimize clinical care. In a prospective cohort study of 366 (291 vaccinated) patients, we measured antibody levels [anti-spike (IgG-(S-RBD) and anti-nucleocapsid immunoglobulin] at three time points. Antibody level trajectories and frequency of breakthrough infections were evaluated by tumor type and timing of treatment relative to vaccination. IgG-(S-RBD) at peak response (median = 42 days after dose 2) was higher (P = 0.002) and remained higher after 4 to 6 months (P = 0.003) in patients receiving mRNA-1273 compared with BNT162b2. Patients with solid tumors attained higher peak levels (P = 0.001) and sustained levels after 4 to 6 months (P < 0.001) compared with those with hematologic malignancies. B-cell targeted treatment reduced peak (P = 0.001) and sustained antibody responses (P = 0.003). Solid tumor patients receiving immune checkpoint inhibitors before vaccination had lower sustained antibody levels than those who received treatment after vaccination (P = 0.043). Two (0.69%) vaccinated and one (1.9%) unvaccinated patient had severe COVID-19 illness during follow-up. Our study shows variation in sustained antibody responses across cancer populations receiving various therapeutic modalities, with important implications for vaccine booster timing and patient selection.Significance: Long-term studies of immunogenicity of SARS-CoV-2 vaccines in patients with cancer are needed to inform evidence-based guidelines for booster vaccinations and to tailor sequence and timing of vaccinations to elicit improved humoral responses.

1 September 2016 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
GMGil Y. Melmed
Gil Y. Melmed
PIPeter M. Irving
Peter M. Irving
JJJennifer Jones
Jennifer Jones
GKGilaad G. Kaplan
Gilaad G. Kaplan
PKPatricia L. Kozuch
Patricia L. Kozuch
CSCorey A. Siegel
Corey A. Siegel